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Purpose: Antidepressant drugs have shown anti-tumor activity in preclinical glioblastoma 
studies. Antidepressant drug use, as well as its association with survival, in glioblastoma patients 
has not been well characterized on a population level. 
Methods: Patient characteristics, including the frequency of antidepressant drug use, were 
assessed in a glioblastoma cohort diagnosed in a 10-year time-frame between 2005 and 2014 in 
the Canton of Zurich, Switzerland. Cox proportional hazards regression models were applied for 
multivariate analysis. Kaplan-Meier survival curves were used to estimate overall survival data 
and the log-rank test was performed for comparisons. 
Results: Four hundred four patients with isocitrate dehydrogenase (IDH) wildtype glioblastoma 
were included in this study. Sixty-five patients (16.1%) took antidepressant drugs at some point 
during the disease course. Patients were most commonly prescribed selective serotonin reuptake 
inhibitors at any time (N=46, 70.8%). Nineteen patients (29.2%) were on antidepressant drugs at 
the time of their tumor diagnosis. No differences were observed in overall survival between those 
patients who had taken antidepressants at some point in their disease course and those who had 
not (p=0.356). These data were confirmed in a multivariate analysis including age, Karnofsky 
performance status, gender, extent of resection, O6-methylguanine DNA methyltransferase 
(MGMT) promoter methylation status, and first-line treatment as cofounders (p=0.315). Also, 
there was no association of use of drugs modulating voltage-dependent potassium channels 
(citalopram; escitalopram) with survival (p=0.639).  
Conclusions: This signal-seeking study does not support the hypothesis that antidepressants have 
antitumor efficacy in glioblastoma on a population level. 
 





Introduction    
Glioblastoma is the most common malignant primary brain tumor in adults 1 Despite multi-modal 
care regimens, including maximum safe tumor resection, radiotherapy and chemotherapy 2,3, 
prognosis remains poor with a median survival of 11 to 14 months 4,5 and a five-year survival rate 
of 5.6% on a population-based level 1. Glioblastoma causes cognitive deficits and psychiatric 
comorbidity, such as depression, anxiety, or fatigue 6-8. The prevalence of depression among 
brain tumor patients has been reported in a wide range of less than 1% 9 to up to 90% 10 of 
patients and is likely highly dependent on the methodology used to assess depressive symptoms. 
Patient-rated analyses showed higher prevalence of depression (27%) than clinician-rated 
measures (15%), as discussed in a systematic review of observational studies on depression in 
glioma 11. This study found a prevalence of depression in about 15% of glioma patients. The 
presence of depressive symptoms may be independently associated with shorter overall survival 
(OS) in glioblastoma patients 12. In preclinical models, tricyclic antidepressants (TCA) such as 
imipramine or amitriptyline, acting as mixed norepinephrine and serotonin uptake inhibitors can 
impair the malignant phenotype of glioma cells by inhibiting cellular respiration, an indicator of 
apoptosis 13,14. Moreover, imipramine and amitriptyline inhibit the expression of p65 NF-κB, 
frequently overexpressed in glioblastoma cells, which results in reduced tumor cell proliferation, 
motility and survival 15,16. In vitro data suggest a role for voltage-dependent potassium channels 
as therapeutic targets in gliomas, which can be modulated by different classes of antidepressants 
17,18. The Kv10.1 subtype of potassium channels is highly expressed in gliomas 19. Imipramine, a 
TCA, binds to these Kv10.1 channels and decreases the proliferation rate of cancer cells 20. 
Glioma cells exhibit a high mitochondrial membrane potential and low expression of Kv1.5 
channels. Citalopram, a selective serotonin reuptake inhibitor (SSRI), acts on the Kv1.5 subtype 





decreased resistance to apoptosis 21,22. Escitalopram, a stereoisomer of citalopram, also inhibits 
voltage-dependent potassium channels, but data regarding its activity against glioma cells are 
lacking 23. Imipramine also inhibits the PI3K/Akt/mTOR signaling pathway and induces 
autophagic cell death in U87MG glioma cells 24. Finally, there is evidence from a mouse model 
suggesting that fluoxetine, a SSRI, can suppress the growth of experimental gliomas by directly 
binding to the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) 25.  
On a population-based level, the prevalence of antidepressant drug use among glioblastoma 
patients, as a surrogate marker for depression or depressive symptoms, as well as the association 







All patients 18 years or older who were inhabitants of the Canton of Zürich, Switzerland and 
diagnosed with glioblastoma between 2005 and 2014 were included in a glioblastoma cancer 
registry in the Canton of Zurich, Switzerland. Patient identification data were provided by the 
Cancer Registry of the Cantons Zurich and Zug. Epidemiological data on this patient cohort have 
been published previously 4,5. For the present analysis, we excluded all patients who lacked 
molecular data on the IDH mutation status based on the present World Health Organization (WHO) 
classification 26, or who had insufficient patient documentation on antidepressant drug use (see 
Supplementary Figure 1).  
 
Disease characteristics 
All tumors in the glioblastoma cancer registry had been classified according to the WHO 2007 
criteria 27 in the local pathology departments, and in a second step were classified by IDH mutation 
status in accordance with the WHO 2016 classification 26. The O6-methylguanine DNA 
methyltransferase (MGMT) promoter methylation status was determined by methylation-specific 
PCR. IDH mutation status was obtained by immunohistochemistry for IDH1 R132H, mainly, based 
on the suggestion that sequencing may not be needed in patients older than 55 years of age 26. 
Extent of resection was determined by early postoperative magnetic resonance imaging (MRI) or, 
if no MRI was available, by cranial computed tomography (CT). Macroscopic (gross) total 
resection was defined by the absence of contrast enhancement 28. Data on use of antidepressant 
drugs were extracted from clinical records. For most patients we had access to all appropriate 
medical records, provided by the caregivers of the patients who we contacted directly. For patients 





time the patient had an appointment. Nevertheless, we cannot exclude that there are patients who 
received antidepressants that we were not aware of. 
 
Statistical analyses 
Demographical, clinical, molecular marker and use of antidepressant drug data were obtained to 
apply descriptive statistics. The Chi-square test was performed for analysis of nominal variables, 
and the Mann-Whitney U test was used for the comparison of quantitative variables between the 
two patient cohorts of antidepressant drug users and non-users. OS was calculated from primary 
surgery to death or last follow-up. Patients were censored at last follow-up. Kaplan-Meier curves 
were used to estimate OS in the antidepressant drug users and non-users, differences were 
analyzed using the log-rank test. Cox proportional hazards regression models were used for 
multivariate analysis to test the association of clinical and molecular factors, as well as use of 
antidepressant drugs with outcome. The multivariate model was applied to all patients who had 
complete information on all tested co-variables. All statistical analyses were performed using 
IBM SPSS, Version 24 (IBM Corporation, Armonk, NY) statistical software, and a p value of 
0.05 was set as statistically significant.   
 
Ethics 
This study was approved by the Ethics Committee of the Canton of Zurich (KEK-ZH-Nr. 2009-








Four hundred four patients with IDH wildtype glioblastoma were included in this retrospective 
study; 65 of these 404 patients (16.1%) took antidepressant drugs at some point during their 
disease course. Patient characteristics of the two subpopulations, the non-antidepressant cohort 
(N=339) and antidepressant cohort (N=65), are summarized in Table 1. Age, gender, KPS, extent 
of resection and first-line treatment after initial surgery were balanced between both patient 
cohorts. Patients who received antidepressants more frequently had a methylated MGMT 
promoter methylation status than patients who did not (p=0.014). The distribution of the KPS 
differed between both patient groups (p=0.033). Comparing the use of antidepressant drugs over 
the analyzed 10-year time-frame, the frequency of use of antidepressant drugs among 
glioblastoma patients decreased over the years from 22.6% (N=40 patients out of N=177 patients) 
in the years 2005 through 2009 to 10.4% (N=25 patients out of N=241 patients) in the years 2010 
through 2014 (p=0.001) (Table 1). 
 
Patterns of antidepressant drug use 
Patients who had taken antidepressant drugs at the time of their glioblastoma diagnosis most 
often received SSRI (68.4%), followed by tetracyclic antidepressants (TeCA) (26.8%), and 
selective serotonin-norepinephrine reuptake inhibitors (SSNRI) (5.3%). After 3 and 6 months 
since beginning to take antidepressants, about half of the patients continued treatment (57.9% and 
47.4%, respectively). When focusing on antidepressants at any time during the course of the 
disease, SSRI were still the most frequently used drugs (70.8%), especially citalopram (33.8%); 
15.4% of all patients received more than only one antidepressant agent (Table 2). Additionally, of 





benzodiazepines at some point during their disease trajectory (see Supplementary Table 1).  
 
Outcome data  
Median OS was 12.8 months (95% confidence interval (CI) 11.4-14.1 months) for patients 
without antidepressant drug use and 10.8 months (95% CI 7.9-13.6 months) for patients who had 
antidepressants at any time during the course of the disease (Table 3). None of the patients 
included in this study were reported to have committed suicide. OS data, estimated using Kaplan-
Meier curves, for both the antidepressant drug using and non-using subgroups are displayed in 
Figure 1A. Although there was a trend towards worse survival in patients with antidepressant 
drug use when compared to non-users, no statistically significant differences were observed 
(p=0.356) (Table 3, Fig. 1A).  
The two patient cohorts, antidepressant - and no antidepressant drug-users, were not balanced 
regarding the MGMT promoter methylation status (Table 1). Therefore, survival curves were 
analyzed separately for patients with tumors with a methylated or unmethylated MGMT 
promoter. A trend towards inferior survival was noticed in both patient cohorts, especially in the 
patients with a methylated MGMT promoter methylation status, but for both patient subgroups 
this did not reach statistically significance (methylated MGMT promoter status p=0.423, 
unmethylated MGMT promoter status p=0.787) (Table 3, see Supplementary Figure 2). 
When analyzing the two 5-year time-frames separately, no association with OS was seen either 
(see Supplementary Table 2). In a subgroup analysis focused on those patients who had used 
antidepressant drugs previously reported to modulate voltage-dependent potassium channels in 
glioma cells 17, such as citalopram (N=22) or escitalopram (N=16) (median OS 10.4 months, 95% 
CI 7.4-13.4), no association with OS was seen compared to patients with any other antidepressant 





(median OS 12.8 months, 95% CI 11.4-14.1; p=0.551) (Fig. 1B).  
 
Multivariate analysis with regards to death 
Multivariate analysis was performed to assess the association of clinical and molecular 
parameters with OS. The analysis confirmed known prognostic or predictive markers in 
glioblastoma, including age, KPS, extent of resection, MGMT promoter methylation status, or 
first-line treatment. Antidepressant drug use at any time during the course of the disease was not 






Antidepressant drugs may be given to glioblastoma patients for different reasons, including 
depression, fatigue, anxiety, or inappetence. These symptoms may be caused by the tumor itself, 
tumor-specific treatments, side-effects of medications, or a psychiatric disorder in the medical 
history 8,11,29. In our cohort study in the Canton of Zurich, Switzerland, 65 patients (16.1%) 
diagnosed with IDH wildtype glioblastoma were on antidepressant drugs at some time during the 
course of disease (Table 1). Assuming that most patients received these drugs because of 
psychiatric morbidities, mainly depressive symptoms and that therefore antidepressant drug use 
can be used as a surrogate marker for depression, the frequency of depression in this cohort is in 
line with data of observational studies published in 2010 11, although higher prevalence rates 
have also been reported 10. This may underline differences in the awareness of psychiatric 
disorders in glioblastoma patients, which can be influenced by social, cultural, and other regional 
factors. Interestingly, use of antidepressant drugs among glioblastoma patients decreased over the 
years in Zurich, Switzerland (see Supplementary Table 2). Not all glioblastoma patients 
diagnosed with psychiatric symptoms receive drugs, and non-medication approaches to 
psychiatric comorbidity may be more compatible with social life. Importantly, there may be an 
increased awareness for such non-pharmaceutical approaches to treating psychiatric symptoms 
and comorbidities in the general population. This is also shown by increased use of 
complementary and alternative medicine (CAM) in glioma patients 30,31. 
Putative molecular mechanisms of anticancer activity of antidepressant drugs include 
modulations of the PI3K/Akt/mTOR signaling pathway 24, AMPAR-mediated calcium-dependent 
apoptosis 25, influencing the mitochondrial machinery 14,21, or targeting voltage-dependent 
potassium channels 17,18. In our population-based study no association was found between the use 





significant, median OS was numerically inferior in the antidepressant cohort compared to patients 
who had no antidepressant drugs, independent of the MGMT promoter methylation status (Table 
3, see Supplementary Figure 2). The same was true when we analyzed the subgroup of patients 
who had taken antidepressant drugs which interfered with voltage-dependent potassium channels, 
including citalopram and escitalopram (both SSRI) (Fig. 1B). In line with our data, in a 
retrospective study, performed at the Mayo Clinic in Rochester, Minnesota, no association of 
SSRI use with survival in glioblastoma patients was found 32. In contrast to our data in 
glioblastoma patients, the opposite was seen in non-central nervous system cancers, such as 
breast cancer 33,34.  
Limitations of our study include the retrospective nature of the study, as well as the lack of data 
on the diagnosis of psychiatric disorders, and intensity of treatment with antidepressants. 
However, medications, including antidepressant drugs, were documented routinely in most 
patients.  Based on the retrospective nature of data collection, the prevalence of drug prescription 
may be underestimated. 
The administration of antidepressant drugs at the time of diagnosis or during the course of the 
disease was not associated with survival in our glioblastoma cohort. This study does not support 
the hypothesis that antidepressant drugs may have antitumor efficacy on a population-based level, 
not excluding the possibility of a subpopulation effect not addressed by our study design. 
However, further investigation, mainly in prospective studies and with a standardized psychiatric 
assessment, may be necessary to dissect any associations of psychiatric comorbidity and the 
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Figure 1.  Antidepressant drugs and survival. 
(A) Kaplan-Meier curves of overall survival are shown for patients who had antidepressant drugs 
(black) or who had no antidepressant drugs (grey) at any time during the course of the disease. 
(B) The same Kaplan-Meier survival curves are shown now stratified for patients who had drugs 
modulating voltage-dependent potassium channels (blue; citalopram, escitalopram) and those 
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N, number of patients; IDH, isocitrate dehydrogenase; KPS, Karnofsky performance score; 
MGMT, O6-methylguanine DNA methyltransferase; RT, radiotherapy; TMZ, temozolomide; CT, 
chemotherapy (mostly alkylating chemotherapy); *, at time of diagnosis; §, mainly experimental 





Table 2. Antidepressant drug use in glioblastoma patients, stratified by mode of action and 
timepoint. 
  
 Antidepressant drug cohort 
Antidepressants at time of diagnosis, N 19 
Type of antidepressant drug, N (% of those with 
















Antidepressants 3 months after diagnosis, N (% of 
those with antidepressant drug use at diagnosis) 
 
Ongoing 







Antidepressants 6 months after diagnosis, N (% of 
those with antidepressant drug use at diagnosis) 
 
Ongoing 










Antidepressants at any time, N 65 
Type of antidepressant drug, N (% of those with any 











SSRI and TeCA 
SSRI and SSNRI 
Multiple SSRIs 















N, number of patients; TCA, tricyclic antidepressant; TeCA, tetracyclic antidepressant; SSRI, 
selective serotonin reuptake inhibitor; SSNRI, selective serotonin-norepinephrine reuptake 
inhibitor; +, patients could have taken more than one antidepressant drug at the same time ++, each 
antidepressant in this category has been counted in its individual group as well.  
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Table 3. Overall survival data, IDH wildtype cohort. 
 
 N (events) Median OS in 
months (95% CI) 
OS 12-months in %  
(SE; remaining cases) 
OS 24-months in %  
(SE; remaining cases) 
P value 
All patients      
No antidepressants  339 (281) 12.8 (11.4-14.1) 54.4 (2.8; 160) 19.0 (2.3; 52) 0.356 
Antidepressants 65 (51) 10.8 (7.9-13.6) 44.3 (6.7; 23) 17.5 (5.4; 8)  
All patients      
Methylated MGMT 
promoter  
127 (101) 14.2 (9.3-19.0) 61.5 (4.5; 68) 31.3 (4.5; 32) 0.004 
Unmethylated MGMT 
Promoter 
160 (136) 12.2 (10.8-13.6) 51.7 (4.2; 71) 14.0 (3.0; 18)  
Patients with a 
methylated MGMT 
promoter  
     
No antidepressants  97 (78) 14.4 (8.7-20.0) 61.2 (5.1; 53) 33.2 (5.1; 26) 0.423 
Antidepressants 30 (23) 13.4 (11.4-15.3) 62.4 (9.4; 16) 25.0 (8.7; 6)  
2 
 
Patients with an 
unmethylated MGMT 
promoter  
     
No antidepressants  140 (121) 12.3 (10.7-13.8) 52.4 (4.4; 64) 12.8 (3.1; 15) 0.787 
Antidepressants 20 (15) 11.9 (6.7-17.1) 45.2 (12.5; 7) 23.2 (11.2; 3)  
 





Table 4. Multivariate analysis with regards to death (cox regression). 
 
 N HR (95% CI) P value 
Age    
> 65 years 120 1 ref 
≤ 65 years 162 0.70 (0.51-0.97) 0.030 
KPS*    
< 70% 67 2.22 (1.58-3.11) <0.001 
70-80% 171 1 ref 
90-100% 44 0.68 (0.46-1.01) 0.054 
Gender    
Male 185 1 ref 
Female 97 1.16 (0.88-1.54) 0.302 
Extent of resection    
Biopsy 50 1 ref 
Incomplete 194 0.38 (0.26-0.56) <0.001 
Gross total (≥ 99%)  38 0.22 (0.13-0.36) <0.001 
MGMT promoter 
methylation status 
   
Unmethylated 159 1 ref 
Methylated 123 0.31 (0.17-0.55) <0.001 
Postsurgical therapy    
No therapy 34 2.67 (1.6-4.48) <0.001 
RT alone 51 1 ref 




RT plus TMZ 156 0.44 (0.29-0.67) <0.001 
Others§ 18 0.40 (0.21-0.77) 0.006 
Antidepressant drug    
No 233 0.83 (0.58-1.19) 0.315 
Yes 49 1 ref 
 
RT, radiotherapy; CT, chemotherapy; TMZ, temozolomide; CI, confidence interval; HR, hazard 
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Supplementary Figure 1. Consort sheet. 
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Supplementary Figure 2. Antidepressant drugs and survival, stratified by MGMT promoter 
methylation status. 
Kaplan-Meier curves of overall survival are shown for patients who had antidepressant drugs 
(black) or who had no antidepressant drugs (grey) at any time during the course of the disease. 
Data are shown for patients diagnosed with glioblastoma with (A) a methylated MGMT 
promoter, or (B) an unmethylated MGMT promoter. The log rank test was used for comparison.  
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Supplementary Table 1. Co-medication of benzodiazepines in glioblastoma patients with 
antidepressant drug use at any time during the course of the disease. 
 
 Antidepressant cohort N = 65 
Benzodiazepine use, N (%) 41 (63.1) 





















Supplementary Table 2. Overall survival data, IDH wildtype cohort, stratified for the two 5-year time-frames. 
 
 N (events) Median OS in 
months (95% CI) 
OS 12-months in %  
(SE; remaining cases) 
OS 24-months in %  
(SE; remaining cases) 
P value 
2010-2014      
No antidepressants  210 (170) 14.2 (12.4-16.0) 60.1 (3.5; 108) 17.0 (2.9; 28) 0.461 
Antidepressants 25 (20) 6.6 (3.5-9.7) 35.9 (10.0; 8) 23.9 (9.6; 4)  
2005-2009      
No antidepressants  129 (111) 11.0 (8.2-13.8) 44.4 (4.6; 51) 21.0 (3.8; 23) 0.804 
Antidepressants 40 (31) 11.9 (9.6-14.2) 46.5 (8.7; 14) 10.0 (5.4; 3)  
 
N, number of patients; OS, overall survival; CI, confidence interval; SE, standard error.  
 
